Catégorie : Substances psychédéliques et therapeutique

Single Shot of Ketamine May Herald ‘Last Call’ for Problem Drinking, Deborah Brauser, 2019

Single Shot of Ketamine May Herald 'Last Call' for Problem Drinking Deborah Brauser Medscape, December 11, 2019 Medscape Medical News © 2019 https://www.medscape.com/viewarticle/922460?src=wnl_tp10n_200116_mscpedit&uac=292598PZ&impID=2238619&faf=1   An experimental treatment that includes a single infusion of ketamine may lead to long-term improvement in problem drinking, new research suggests. In an study of 90 heavy drinkers, those who received a single dose of intravenous (IV) ketamine plus cognitive behavioral therapy (CBT) that focused on reactivating drinking-related "maladaptive reward memories" (MRMs) significantly curbed the urge to drink and reduced alcohol intake  compared with those who received the ketamine alone or a placebo infusion. In addition, the combination group reduced their average weekly alcohol consumption by [...]

Lire la suite

The Confrontation between Ethnopharmacology and Pharmacological Tests of Medicinal Plants Associated with Mental and Neurological Disorders, Giovanna Felipe Cavalcante e Costa et al., 2018

The Confrontation between Ethnopharmacology and Pharmacological Tests of Medicinal Plants Associated with Mental and Neurological Disorders Giovanna Felipe Cavalcante e Costa, Hisao Nishijo, Leonardo Ferreira Caixeta, and Tales Alexandre Aversi-Ferreira Hindawi - Evidence-Based Complementary and Alternative Medicine, Volume 2018, Article ID 7686913, 27 pages Doi : 10.1155/2018/7686913   Abstract For neurological disorders, pharmacological tests have shown promising results in the reduction of side effects when using plants with known therapeutic effects in the treatment of some types of dementia. Therefore, the goals of this study are to gather data about the major medicinal plants used in the nervous system as described in ethnopharmacological surveys from South [...]

Lire la suite

Translational evidence for ayahuasca as an antidepressant : what’s next ?

Translational evidence for ayahuasca as an antidepressant : what’s next ? Rafael Guimaraes dos SANTOS, José Carlos BOUSO British Journal of Psychiatry, 2019, 41, (4), 275-276. Doi : 10.1590/1516-4446-2019-4104   Depression is among the most important contributors to global disability and suicidal deaths. Available antidepressants are usually selective inhibitors of serotonin and norepinephrine uptake, which need weeks of daily intake before therapeutic effects appear, have limited efficacy for many patients, and induce significant adverse reactions after prolonged use. Therefore, recent research has focused on finding new antidepressant compounds that are fast-acting, more effective, and less toxic. The article recently published by da Silva et al. in the [...]

Lire la suite

d-Lysergic acid diethylamide has major potential as a cognitive enhancer, Felipe Augusto Cini et al., 2019

d-Lysergic acid diethylamide has major potential as a cognitive enhancer Felipe Augusto Cini, Isis Ornelas, Encarni Marcos, Livia Goto-Silva, Juliana Nascimento, Sergio Ruschi, José Salerno, Karina Karmirian, Marcelo Costa, Eduardo Sequerra, Dráulio de Araújo, Luis Fernando Tófoli, César Rennó-Costa, Daniel Martins-de-Souza, Amanda Feilding, Stevens Rehen, Sidarta Ribeiro BioRxiv, 6 december 2019. Doi : 10.1101/866814   Abstract Psychedelic agonists of serotonin receptors induce neural plasticity and synaptogenesis, but their potential to enhance learning remains uncharted. Here we show that a single dose of d-LSD, a potent serotonergic agonist, increased novel object preference in young and adult rats several days after treatment. d- LSD alone did not increase preference [...]

Lire la suite

Études psychédéliques, séminaire, Vincent Verroust, doctorant à l’EHESS, 2019-2020

Études psychédéliques Vincent Verroust, doctorant à l'EHESS ( CAK )Cet enseignant est référent pour cette UE https://enseignements-2019.ehess.fr/2019/ue/2998/   Mardi de 18 h à 19 h 30 (amphithéâtre Rouelle, Muséum national d'Histoire naturelle, 57 rue Cuvier 75005 Paris), les 26 novembre, 17 décembre 2019, 28 janvier, 25 février, 31 mars, 28 avril, 26 mai et 30 juin 2020 Plan pour trouver l'amphi : https://drive.google.com/file/d/1h-oVy6oTh7UTMh84X-o448VhCCmBMp-M/view?usp=sharing NB : merci d'arriver en avance pour éviter de trouver portes closes. Le terme psychedelic a été forgé en 1956 par le psychiatre britannique Humphry Osmond (1917 - 2004) pour qualifier les effets psychiques de la mescaline et du LSD, deux substances psychotropes sur lesquelles [...]

Lire la suite

The Philosophy of Psychedelic Transformation, Chris Letheby,

The Philosophy of Psychedelic Transformation Chris Letheby Journal of Consciousness Studies.     Introduction and Methodological Preliminaries Psychedelic drugs are remarkable substances which have been hailed as indispensable epistemic instruments for the sciences of mind, as unparalleled psychotherapeutic interventions, as unique sources of insight into the nature and genesis of psychosis and religion, and as keys to the survival and flourishing of the human species (Osmond 1957, Sessa 2012). After a politically driven decades long hiatus, scientific study of these drugs in humans has resumed with impressive results. Given the magnitude and variety of significance ascribed to the substances, it is surprising that philosophers have not [...]

Lire la suite

Australia should be initiating a psychedelic research program : What are the barriers ?, Nigel Strauss et al., 2016

Australia should be initiating a psychedelic research program : What are the barriers ? Nigel Strauss, Stephen J Bright and Martin L Williams Australian & New Zealand Journal of Psychiatry, 2016, Vol. 50, (11), 1036–1037 DOI: 10.1177/0004867416670520   A recent review in Pharmacological Reviews highlights that over the last decade, a renaissance has occurred in psychedelic drug research in North America and Europe as investigators at Johns Hopkins School of Medicine, University of California, Los Angeles (UCLA), New York University and Imperial College London have embarked on studies that could be paradigm-changing for psychiatry (Nichols, 2016). These developments overturn a 30-year embargo on psychedelic research [...]

Lire la suite

Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers, Rainer Kraehenmann et al., 2014

Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers Rainer Kraehenmann, Katrin H. Preller, Milan Scheidegger, Thomas Pokorny, Oliver G. Bosch, Erich Seifritz, and Franz X. Vollenweider Biological Psychiatry, 2014. http://dx.doi.org/10.1016/j.biopsych.2014.04.010   Background : The amygdala is a key structure in serotonergic emotion-processing circuits. In healthy volunteers, acute administration of the serotonin 1A/2A/2C receptor agonist psilocybin reduces neural responses to negative stimuli and induces mood changes toward positive states. However, it is little known whether psilocybin reduces amygdala reactivity to negative stimuli and whether any change in amygdala reactivity is related to mood change. Methods : This study assessed the effects of [...]

Lire la suite

Patient Experiences of Psilocybin-Assisted Psychotherapy : An Interpretative Phenomenological Analysis, Alexander B. Belser et al., 2017

Patient Experiences of Psilocybin-Assisted Psychotherapy : An Interpretative Phenomenological Analysis Alexander B. Belser, Gabrielle Agin-Liebes, T. Cody Swift, Sara Terrana, Neşe Devenot, Harris L. Friedman, Jeffrey Guss, Anthony Bossis and Stephen Ross Journal of Humanistic Psychology, 2017, 1 –35 Doi : 10.1177/0022167817706884 journals.sagepub.com/home/jhp   Abstract The psychological mechanisms of action involved in psilocybin-assisted psychotherapy are not yet well understood. Despite a resurgence of quantitative research regarding psilocybin, the current study is the first qualitative study of participant experiences in psilocybin-assisted psychotherapy. Semistructured interviews were carried out with 13 adult participants aged 22 to 69 years (M = 50 years) with clinically elevated anxiety associated with a cancer [...]

Lire la suite

Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans, José Carlos Bouso et al., 2015

Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans José Carlos Bouso, FernandaPalhano-Fontes, Antoni Rodríguez-Fornells, Sidarta Ribeiro, Rafael Sanches, José Alexandre S. Crippa, Jaime E.C. Hallak, Draulio B. de Araujo, Jordi Riba European Neuropsychopharmacology, 2015, 25, 483–492 http://dx.doi.org/10.1016/j.euroneuro.2015.01.008 Abstract Psychedelic agents have a long history of use by humans for their capacity to induce profound modifications in perception,emotion and cognitive processes. Despite increasing knowledge of the neural mechanisms involved in the acute effects of these drugs, the impact of sustained psychedelic use on the human brain remains largely unknown. Molecular pharmacology studies have shown that psychedelic 5-hydroxytryptamine (5HT)2A [...]

Lire la suite